Latest Manufacturing News

Weebit Nano reports solid progress in Q4 FY25 with key technology milestones and its first product design license, backed by a strong cash position.

Skin Elements Limited advances its proprietary SE Formula biotechnology with ECO-Nurture poised for commercial rollout in 2026, alongside progress in disinfectant and sunscreen product lines.

Renascor Resources has achieved provisional development approval for its commercial-scale Battery Anode Material manufacturing facility, alongside significant progress in graphite production and exploration activities. The company maintains a robust cash position of A$105 million as it advances its vertically integrated graphite project.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.

Cadoux Limited has made significant progress in developing its high purity alumina and rare earths projects, advancing engineering design, customer engagement, and funding strategies during the June 2025 quarter.

Delorean Corporation has marked significant progress in Q4 FY2025, advancing its renewable gas infrastructure and securing crucial regulatory support that could unlock new revenue streams.

Audio Pixels Holdings reports a delay in its MEMS wafer production due to a key fabrication step requiring revision, while its shares remain suspended on the ASX. The company signals the need for additional funding within six months to sustain its R&D efforts.

Cambium Bio has cleared key regulatory hurdles for its lead dry eye disease treatment, Elate Ocular, and strengthened its balance sheet with a $2.12 million placement to support upcoming Phase 3 trials.

Fintech Chain Limited reported a mixed quarter with strong customer receipts and new IoT SaaS product launch, while finalising its ASX delisting. The company’s cash position tightened amid loan repayments and rising operating costs.

ABx Group Limited reports promising rare earth exploration results in Tasmania, steady progress on its ALCORE fluorine recycling pilot plant, and advancing bauxite mining projects in Queensland and Tasmania, while managing funding challenges.